(Q35962549)

11 August 2017

1 reference

title

Orlistat: a review of its use in the management of patients with obesity (English)

1 reference

11 August 2017

0 references

2

Lesley J Scott

1 reference

11 August 2017

1

Monique P Curran

1 reference

PubMed ID

15563254

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

64

1 reference

11 August 2017

2845-2864

1 reference

11 August 2017

24

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200464240-00010

11 August 2017

0 references

cites work

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers.

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers

1 reference

12 December 2020

Effects of orlistat on obesity-related diseases - a six-month randomized trial

1 reference

12 December 2020

Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions

1 reference

12 December 2020

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

1 reference

12 December 2020

Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns

1 reference

12 December 2020

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients

1 reference

12 December 2020

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

1 reference

12 December 2020

Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions

1 reference

12 December 2020

Obesity in women from developing countries

1 reference

12 December 2020

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

1 reference

12 December 2020

Economic Evaluation of Orlistat in Overweight and Obese Patients with Type 2 Diabetes Mellitus

1 reference

12 December 2020

The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers

1 reference

12 December 2020

Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement

1 reference

12 December 2020

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingd

1 reference

12 December 2020

Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers

1 reference

12 December 2020

Weight change and blood coagulability and fibrinolysis in healthy obese women

1 reference

12 December 2020

Orlistat in the long-term treatment of obesity in primary care settings

1 reference

12 December 2020

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

12 December 2020

Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients

1 reference

12 December 2020

The disease burden associated with overweight and obesity

1 reference

12 December 2020

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

1 reference

12 December 2020

Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults

1 reference

12 December 2020

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial

1 reference

12 December 2020

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

12 December 2020

Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

1 reference

12 December 2020

Orlistat: in the prevention and treatment of type 2 diabetes mellitus

1 reference

12 December 2020

The burden of chronic hyperglycemia

1 reference

12 December 2020

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

1 reference

12 December 2020

The beneficial effects of modest weight loss on cardiovascular risk factors

1 reference

12 December 2020

Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor

1 reference

12 December 2020

Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

1 reference

12 December 2020

The cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesity

1 reference

12 December 2020

Mode of action of orlistat

1 reference

12 December 2020

Strategies for the management of patients with obesity

1 reference

12 December 2020

Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet

1 reference

12 December 2020

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

1 reference

12 December 2020

Orlistat: a review of its use in the management of obesity

1 reference

12 December 2020

Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects

1 reference

12 December 2020

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers

1 reference

12 December 2020

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).

1 reference

12 December 2020

The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers

1 reference

12 December 2020

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women.

1 reference

12 December 2020

Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity

1 reference

12 December 2020

Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study.

1 reference

12 December 2020

Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients

1 reference

12 December 2020

The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers

1 reference

12 December 2020

Human leptin: from an adipocyte hormone to an endocrine mediator

1 reference

12 December 2020

Effects of orlistat on fat-soluble vitamins in obese adolescents

1 reference

12 December 2020

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

12 December 2020

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.

1 reference

12 December 2020

Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers

1 reference

12 December 2020

Managing type 2 diabetes mellitus in patients with obesity

1 reference

12 December 2020

Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations

1 reference

12 December 2020

The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes

1 reference

12 December 2020

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.

1 reference

12 December 2020

The Effect of Short-Term (21-Day) Orlistat Treatment on the Physiologic Balance of Six Selected Macrominerals and Microminerals in Obese Adolescents

1 reference

12 December 2020

Lack of interaction between orlistat and oral contraceptives

1 reference

12 December 2020

Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature

1 reference

12 December 2020

Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia

1 reference

12 December 2020

Effects of Orlistat, a Lipase Inhibitor, on the Pharmacokinetics of Three Highly Lipophilic Drugs (Amiodarone, Fluoxetine, and Simvastatin) in Healthy Volunteers

1 reference

12 December 2020

The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial

1 reference

12 December 2020

Pharmacological approaches to weight reduction: therapeutic targets

1 reference

12 December 2020

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

1 reference

12 December 2020

Current and investigational antiobesity agents and obesity therapeutic treatment targets

1 reference

12 December 2020

Orlistat inhibits dietary cholesterol absorption

1 reference

12 December 2020

The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study

1 reference

12 December 2020

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

1 reference

12 December 2020

Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity

1 reference

12 December 2020

Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss

1 reference

12 December 2020

Influence of orlistat on bone turnover and body composition

1 reference

12 December 2020

Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat

1 reference

12 December 2020

Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers

1 reference

12 December 2020

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women

1 reference

12 December 2020

The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines

1 reference

12 December 2020

Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: A 12-week, randomized, placebo-controlled study

1 reference

12 December 2020

10.2165/00003495-200464240-00010

Identifiers

DOI

1 reference

PubMed ID

15563254

Dimensions Publication ID

11 August 2017

0 references

1 reference

PubMed ID

15563254